|
시장보고서
상품코드
2058351
식물성 및 식물 유래 의약품 시장 : 원료별, 제형별, 치료 용도별, 지역별Botanical and Plant Derived Drugs Market, By Source, By Dosage Form, By Therapeutic Application, By Geography |
||||||
식물성 및 식물 유래 의약품 시장은 2026년에 526억 달러에 달하고 2033년까지 807억 달러에 이를 전망입니다. 2026-2033년 CAGR은 6.3%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 526억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 6.30% | 시장 규모 예측(2033년) : | 807억 달러 |
식물성 및 식물 유래 의약품에는 식물에서 추출한 유효 성분이 포함되어 있습니다. 식물성 및 식물 유래 의약품이란 식물 전체, 식물의 일부, 균류 또는 조류를 포함한 식물성 원료의 혼합물을 말합니다. 식물은 예로부터 의약품의 원료로 이용되어 왔으나, 합성 의약품 복용으로 인한 부작용을 우려하여 합성 의약품보다 식물성 및 식물 유래 의약품이 선호되는 추세입니다.
또한, 식물성 의약품은 기존 의약품과 마찬가지로 안전성과 유효성에 대한 임상 평가가 이루어지고 있습니다. 또한, 의료용 대마의 합법화 역시 식물성 및 식물 유래 의약품 시장의 성장을 가속할 것으로 예측됩니다.
시장 역학
세계 식물성 및 식물 유래 의약품 시장은 의료용 대마의 합법화로 인해 예측 기간 동안 상당한 성장이 예상됩니다. 의료용 대마는 2013년 체코에서 2015년 아르헨티나와 칠레에서 합법화되었습니다. 또한 2016년에는 일부 주에서 의료용 대마초가 합법화되면서, 미국 내 대마초 합법화가 전환점을 맞이했습니다.
따라서 많은 제약사가 신약 출시를 목표로 의료용 대마의 연구 개발에 주력하고 있습니다. 예를 들어, GW 파마슈티컬스사의 의약품 중 하나인 '에피디오렉스(Epidiolex)'는 칸나비디바린(CBDV)을 주성분으로 하는 개발 중인 약제로, 2016년에 뉴사우스웨일스주 및 퀸즐랜드주 정부의 지원을 받아 치료 저항성 간질에 대한 임상시험에 사용될 예정입니다.
또한, 만성 질환 증가는 식물성 및 식물 유래 의약품 시장의 성장을 가속하고 있습니다. 동아시아, 남아시아, 동남아시아에서는 폐암이 사망 원인 1위를 차지하고 있기 때문입니다. 『Cancer Atlas』의 통계에 따르면, 이 지역은 전 세계 인구의 56%를 차지하며, 전 세계 암 환자의 44%를 차지하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 세계 식물성 및 식물 유래 의약품 시장의 주요 기업 프로파일을 작성하였습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 정부의 정책, 시장 확대 및 마케팅 전략과 관련하여 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 『세계 식물성 및 식물 유래 의약품 시장 보고서』는 투자자, 제품 제조업체, 유통업체, 공급업체, 조사·컨설팅 회사, 신규 진출기업, 금융 애널리스트 등 해당 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적 및 전제 조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 식물성 및 식물 유래 의약품 시장 : 원료별(2021-2033년)
제5장 세계의 식물성 및 식물 유래 의약품 시장 : 제형별(2021-2033년)
제6장 세계의 식물성 및 식물 유래 의약품 시장 : 치료 용도별(2021-2033년)
제7장 세계의 식물성 및 식물 유래 의약품 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
KTH 26.06.19Botanical And Plant Derived Drugs Market is estimated to be valued at USD 52.6 Bn in 2026 and is expected to reach USD 80.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 52.6 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.30% | 2033 Value Projection: | USD 80.7 Bn |
Botanical and plant derived drugs contain active ingredients derived from plants. The botanical drug is a mixture of plant materials that include whole plant, part of plants, fungi or algae. Plants have been used as a source of medicine since past, owing to side effects caused due to consumption of synthetic drugs the botanical and plant derived drugs are preferred over the synthetic drugs.
Furthermore, the botanical drugs are clinically evaluated for safety and efficacy just as conventional drugs. Besides, this legalization of medical cannabis is also expected to foster growth of the botanical and plant derived drugs market.
Market Dynamics
The global botanical and plant derived drugs market is projected to witness significant growth over the forecast period, owing to legalization of medical cannabis. Medical cannabis was legalized in the Czech Republic, in 2013, Argentina and Chile in 2015, and in 2016, marijuana legalization in America reached a tipping point, as the medical marijuana became legal in some of the states.
Hence, many manufacturers are focused on research and development on medical cannabis to launch new drugs. For instance, one of the drug by GW Pharmaceuticals, Epidiolex consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016.
Furthermore, increasing number of chronic disease supports the growth of botanical and plant derived drugs, as lung cancer accounts for the leading cause of death in the Eastern, Southern and Southeastern Asia. The region holds for 56% of the world's population and contributes to 44% of the total cancer cases worldwide according to the statistics mentioned in the Cancer Atlas.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global botanical and plant derived drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key companies covered as a part of this study include Bayer Healthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals, Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Concordia Pharmaceuticals, GW Pharmaceuticals, LEO Pharma, MEDICAGO, and Merck.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, market expansion, and marketing tactics.
- The global botanical and plant derived drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for botanical and plant derived drugs market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
- By Source (Revenue, USD Bn, 2021-2033)
- Plant
- Algae
- Macroscopic fungi
- Others
- By Dosage Form (Revenue, USD Bn, 2021-2033)
- Pills
- Tablets
- Capsules
- Injection
- By Therapeutic Application (Revenue, USD Bn, 2021-2033)
- Central Nervous System
- Cardiovascular Diseases
- Infectious Diseases
- Respiratory Diseases
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- South Africa
- Central Africa
- Key Players
- Bayer Healthcare
- GlaxoSmithKline
- Pfizer, Inc.
- Sanofi
- Actelion Pharmaceuticals
- Aimil Pharmaceuticals
- Allergan
- AstraZeneca
- Boehringer Ingelheim
- GW Pharmaceuticals
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Botanical and Plant Derived Drugs Market, By Source
- Global Botanical and Plant Derived Drugs Market, By Dosage Form
- Global Botanical and Plant Derived Drugs Market, By Therapeutic Application
- Global Botanical and Plant Derived Drugs Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Recent product launches
- Regulatory Scenario
- Awareness initiatives
- PEST Analysis
- PORTER's Analysis
- Epidemiology
4. Global Botanical and Plant Derived Drugs Market, By Source, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Plant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Algae
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Macroscopic fungi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
5. Global Botanical and Plant Derived Drugs Market, By Dosage Form, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Pills
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
6. Global Botanical and Plant Derived Drugs Market, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
7. Global Botanical and Plant Derived Drugs Market, By Regions, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Source, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Countries, 2021 - 2033, (US$ Billion)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Source, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Countries, 2021 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Latin America
- Market Size and Forecast, By Source, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Countries, 2021 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Asia Pacific
- Market Size and Forecast, By Source, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Countries, 2021 - 2033, (US$ Billion)
- China
- India
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Source, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Countries, 2021 - 2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Source, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Countries, 2021 - 2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Bayer Healthcare
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Actelion Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Aimil Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Allergan
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GW Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Bayer Healthcare
9. Section
- References
- Research Methodology
- About Us and Sales Contact
